Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Neo-Kidney Augment

Cell therapy · developed by Prokidney

Phase 2 Most advanced trial (none active)
PROK Developer
1 Registered trials

What is Neo-Kidney Augment?

Neo-Kidney Augment is a cell therapy made from expanded autologous selected renal cells derived from the patient's own kidney biopsy, formulated in a gelatin-based hydrogel for administration. It is studied in chronic kidney disease and type 2 diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Therapy area
Metabolic, Renal & urology
Developer
Prokidney (PROK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02525263 Phase 2 Chronic Kidney Disease Terminated PROK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Kidney DiseaseType 2 Diabetes

More from Prokidney

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PROK page.

Follow PROK, the company behind Neo-Kidney Augment

See PROK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PROK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.